FAT4 and hematopoietic and lymphoid system neoplasm: Notably, the prognostic impact of FAT4 has never been reported in hematologic tumors but it was recurrently mutated in primary central nervous system lymphoma [39], gastrointestinal DLBCL [40], and splenic marginal zone lymphoma [41].